Investment Rating - The report does not explicitly state an investment rating for the industry or specific companies. Core Insights - The report highlights significant developments in the overseas pharmaceutical sector, including the collaboration between Insilico Medicine and Heng Tai Biopharma to develop a novel NLRP3 inhibitor for central nervous system diseases [2][6]. - The report notes that MicroPort Robotics expects a revenue growth of approximately 110%-120% year-on-year for 2025, with an adjusted net loss not exceeding 240 million yuan, representing a reduction of over 50% [5][6]. - GSK has reached a final agreement to acquire RAPT Therapeutics for approximately 2.2 billion USD, focusing on a long-acting monoclonal antibody currently in clinical trials [7][8]. Summary by Sections 1. Overseas Pharmaceuticals - Insilico Medicine and Heng Tai Biopharma have entered a partnership to develop ISM8969, a novel oral NLRP3 inhibitor, with both companies holding 50% global rights [2][6]. - The Hong Kong Stock Exchange has approved the full circulation of 182,645,856 H shares for Fuhong Hanlin, representing about 33.61% of the company's total issued shares as of January 19 [2][6]. - The new drug application for TLX591-CDx, a radiopharmaceutical for prostate cancer diagnosis, has been accepted by the NMPA [2][6]. 2. Company Updates - MicroPort Robotics has reported over 180 commercial orders and more than 120 installations globally as of January 21 [5][6]. - Legend Biotech, a joint venture of Genscript Biotech, reported a trade sales net of approximately 555 million USD for the quarter ending December 31, 2025 [5][6]. - GSK's acquisition of RAPT Therapeutics includes a payment of 58.00 USD per share, with an expected upfront investment of 1.9 billion USD after cash adjustments [7][8]. 3. Market Performance - The Hang Seng Healthcare Index fell by 4.35%, underperforming the Hang Seng Index by 3.26 percentage points [4]. - The report indicates a strong performance in the overseas education sector, with GMV for Dongfang Zhenxuan reaching approximately 310 million yuan, a 42.8% increase week-on-week [15][16]. 4. Recommendations - The report suggests focusing on innovative drugs and the ongoing clinical progress of key pipelines from companies such as BeiGene, Innovent Biologics, and others [12]. - It also recommends monitoring the performance of educational companies like Dongfang Zhenxuan and China Oriental Education, which are expected to benefit from improved operational strategies and increased enrollment [16].

Core Viewpoint - The innovation-driven pharmaceutical sector in China is experiencing significant growth, with a shift from traditional growth drivers to innovative ones, supported by demographic changes and advancements in technology [1]. Group 1: Industry Transformation - The Chinese pharmaceutical industry has completed a transformation from old to new growth drivers between 2015 and 2025, with innovation opening new growth trajectories for companies [1]. - Traditional pharmaceutical companies have successfully transitioned to innovation-focused models, enhancing their global competitiveness [1]. Group 2: Market Dynamics - The demand side is bolstered by an aging population and an increase in chronic disease prevalence, while the payment side benefits from stable growth in medical insurance revenues and the establishment of a multi-tiered payment system [1]. - The rapid development of new technologies, such as AI, brain-computer interfaces, and cancer early screening, is expected to drive further industry transformation and growth [1]. Group 3: Investment Opportunities - The Cathay Innovation Drug ETF (517110) has seen over 1.4% increase in intraday trading and has experienced net inflows for five consecutive days, indicating strong investor interest in innovation-focused pharmaceutical technology [1]. - The ETF tracks the SHS Innovation Drug Index (931409), which selects listed companies with strong R&D capabilities and growth potential in the biopharmaceutical and chemical pharmaceutical sectors [1].

Investment Rating - The industry is rated as "Neutral" [8][60] - Specific company ratings include "Buy" for 恒瑞医药 (Hengrui Medicine) and "Increase" for 药明康德 (WuXi AppTec) [8][60] Core Insights - The report highlights the issuance of opinions by nine departments, including the Ministry of Commerce, aimed at promoting high-quality development in the pharmaceutical retail industry, indicating a potential turning point for pharmacy operations [8][16] - The report emphasizes the expected benefits for leading chain pharmacies from policy support and increased industry concentration [8][16] - The inclusion of the drug替尔泊肽 (Tirzepatide) as a breakthrough therapy for treating metabolic-associated fatty liver disease is noted as a significant development [8][16] Industry News - The National Medical Insurance Administration issued a guideline for the pricing of surgical and treatment auxiliary services, consolidating existing price projects into 37 items [16] - The report discusses the promotion of pharmaceutical retail industry transformation towards a "health service hub" through enhanced pharmacy services and optimized purchasing experiences [16][17] - The report mentions the ongoing development of AI applications in healthcare and pharmaceuticals, suggesting investment opportunities in AI-related companies [8][58] Industry Data - As of January 22, 2026, the price index for traditional Chinese medicine shows a year-on-year decline of 14%, with specific herbs like 连翘 (Forsythia) and 党参 (Codonopsis) experiencing significant price drops of 31% and 36% respectively [18][23] - The SW pharmaceutical industry’s price-to-earnings ratio (TTM) is reported at 52.01 times, with a valuation premium of 266% relative to the CSI 300 index [52] Company Announcements - 恒瑞医药 (Hengrui Medicine) received clinical trial approval for multiple drugs, including SHR-7787 and 阿得贝利 (Adalimumab) [30] - 百利天恒 (Baili Tianheng) has had its drug application for treating recurrent or metastatic esophageal squamous cell carcinoma accepted [31] - 复星医药 (Fosun Pharma) announced plans to spin off a subsidiary for listing and received clinical trial approval for a drug targeting advanced colorectal cancer [35]

Investment Rating - The report maintains a "Market Perform" rating for the pharmaceutical and biotechnology industry, indicating that the industry index is expected to perform within ±10% of the market index over the next six months [4][26]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the Shanghai and Shenzhen 300 index, with a decline of 0.75% from January 9 to January 22, 2026, lagging behind the index by approximately 0.46 percentage points [11]. - Most sub-sectors within the industry recorded positive returns during the same period, with offline pharmacies and raw materials leading the gains at 3.14% and 2.34%, respectively. In contrast, the pharmaceutical distribution and chemical preparation sectors experienced declines of 3.26% and 2.87% [12][13]. - Approximately 66% of stocks in the industry recorded positive returns, with the top performer, Baolait, showing a weekly increase of 60.88%. Conversely, Luyan Pharmaceutical had the largest decline at 39.07% [13][16]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry index showed a decline of 0.75%, underperforming the Shanghai and Shenzhen 300 index by 0.46 percentage points [11]. - Most sub-sectors achieved positive returns, particularly offline pharmacies and raw materials, while pharmaceutical distribution and chemical preparations faced declines [12]. 2. Industry News - Recent policy changes in Hebei Province have lifted restrictions on the quantity of drugs that hospitals can stock, allowing for more flexibility in drug procurement and usage [24]. 3. Company Announcements - Enhua Pharmaceutical announced the approval of its drug registration certificate for a new injection, which is expected to enhance its market position [25]. 4. Industry Outlook - The report suggests a focus on investment opportunities in the brain-computer interface sector, which is highlighted as a key area for future growth. Specific companies to watch include Mindray Medical, Yuyuan Medical, and others across various segments [26][28].

Group 1 - The core viewpoint is that Hong Kong's technology leaders are accelerating the integration of AI with their business ecosystems, with Alibaba and Tencent leading the charge in productization and application expansion [1] - Alibaba is leveraging its Qianwen platform to enhance product offerings in core scenarios such as e-commerce and transportation, while Tencent is using its WeChat ecosystem to lower development barriers for AI applications [1] - The growth momentum of Alibaba Cloud's overseas business is strong, and the recent performance of domestic semiconductor and hard tech companies listed in Hong Kong is robust, indicating a continued influx of quality tech firms to the Hong Kong market [1] Group 2 - The Hong Kong Stock Connect Technology Index has a higher allocation in sectors like new energy vehicles, innovative pharmaceuticals, and semiconductors compared to the Hang Seng Technology Index [2] - From the base date at the end of 2014 to the end of 2025, the cumulative return of the Hong Kong Stock Connect Technology Index is 224.25%, significantly outperforming the Hang Seng Technology Index, which has a return of 83.87% [2] - The Hong Kong Stock Connect Technology Index has consistently outperformed other indices, including the Shanghai-Hong Kong-Shenzhen Internet Index and the Hang Seng Healthcare Index [2]

Investment Rating - The report gives a "Market Weight" rating for the pharmaceutical and biotechnology industry, indicating that the industry index is expected to perform within ±10% of the market index over the next six months [26]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 0.75% from January 9 to January 22, 2026, which is approximately 0.46 percentage points lower than the CSI 300 index [11]. - Most sub-sectors within the industry recorded positive returns during the same period, with offline pharmacies and raw materials sectors leading with increases of 3.14% and 2.34%, respectively [12]. - Approximately 66% of stocks in the industry recorded positive returns, with the top performer, Baolait, seeing a weekly increase of 60.88% [13]. - The overall price-to-earnings (P/E) ratio for the SW pharmaceutical and biotechnology industry was approximately 52.01 times as of January 22, 2026, showing little change [19]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry lagged behind the CSI 300 index, with a decline of 0.75% from January 9 to January 22, 2026 [11]. - Most sub-sectors achieved positive returns, particularly offline pharmacies and raw materials, which rose by 3.14% and 2.34% respectively [12]. - About 66% of stocks in the industry had positive returns, with Baolait leading at a 60.88% increase [13]. - The industry’s P/E ratio was approximately 52.01 times, relative to the CSI 300's P/E ratio of 3.86 times [19]. 2. Industry News - Recent policy changes in Hebei Province have lifted restrictions on the quantity of drugs that hospitals can stock, allowing for more flexibility in drug procurement [24]. - The National Health Commission issued new medical treatment guidelines for trauma and burn victims to enhance emergency response capabilities [22][23]. 3. Company Announcements - Enhua Pharmaceutical announced the approval of a new drug registration certificate for a non-steroidal anti-inflammatory drug, which is expected to reduce the need for opioid pain relief post-surgery [25]. 4. Industry Outlook - The report suggests a focus on investment opportunities in the brain-computer interface sector, which is highlighted in the 14th Five-Year Plan, with ongoing policy support [26]. - Recommended stocks for attention include leading companies in medical devices, pharmaceutical retail, aesthetic medicine, and innovative drugs, among others [28].

Core Viewpoint - The market is experiencing significant differentiation as of Q4 2025, with a focus on the balance between returns, cycles, and risks rather than just the correctness of investment directions [1] Group 1: Fund Manager Insights - Fund manager Yao Zhipeng has been with Harvest Fund since 2011, focusing on growth and industry directions, and has extensive experience managing various product types [1][2] - The total scale of products managed by Yao Zhipeng is approximately 20 billion yuan, with Harvest Power Pioneer being a representative product [2] Group 2: Portfolio Composition - The top ten holdings of Harvest Power Pioneer include Ningde Times, Xinda Bio, Hunan Youneng, WuXi AppTec, O-film Tech, Zhongkuang Resources, Putailai, Nongfu Spring, Tianqi Lithium, and Xiaopeng Motors, indicating a multi-line structure [2][3] - The portfolio is built on three clear lines: 1. New energy, lithium battery, and new energy vehicle industry chain [3] 2. Pharmaceutical and innovative assets, reflecting ongoing attention to the innovative drug industry chain [3] 3. Consumer goods, with Nongfu Spring being one of the few hundred billion-level products in the food and beverage sector [4] Group 3: Market Environment Analysis - The overall market in Q4 2025 is characterized by a steady rise, with good returns in commercial aerospace, copper and aluminum commodities, chemicals, communications, and insurance, while cyclical assets have adjusted [4][5] - Yao Zhipeng expresses a cautious and neutral stance on the technology sector, highlighting the crowded nature of tech investments and the reevaluation of risks associated with AI [5][6] Group 4: Economic Outlook and Investment Strategy - The primary task for the Chinese economy in 2026 is to expand domestic demand, which will likely influence investment directions [6][7] - Long-term favored directions include new energy, new technology, new consumption, and innovative drugs, focusing on lithium batteries, embodied intelligent applications, and consumer assets that align with improving consumption [7] - Attention is also drawn to the potential for foreign capital inflow due to the appreciation of the RMB and the attractiveness of leading companies in various industries [8][9] Group 5: Portfolio Adjustment Strategy - Yao Zhipeng plans to gradually increase allocations to domestic demand and cyclical leading assets, enhancing the balance of the portfolio while dynamically adjusting based on macro and mid-level environmental changes [8][9]

Group 1 - The Hong Kong pharmaceutical sector is experiencing a strong rebound, with the Hong Kong Stock Connect Innovation Drug ETF (159570) rising nearly 2% and achieving a transaction volume exceeding 700 million yuan in a short period [1] - The ETF has seen a cumulative net inflow of over 430 million yuan in the past five days, with its latest scale surpassing 25.1 billion yuan, leading in its category [1] - The majority of the weighted stocks in the ETF's index have shown positive performance, including Kangfang Biopharma and Kelun-Botai, which both rose over 4% [3][4] Group 2 - Kangfang Biopharma announced that its new humanized anti-IL-17A monoclonal antibody, AK111, has received acceptance for a new drug application for treating active ankylosing spondylitis (AS) by the National Medical Products Administration (NMPA) [3] - This new drug is expected to provide a new treatment option for nearly 4 million AS patients in China [3] - The JPMorgan Healthcare Conference highlighted the achievements of Chinese innovative drug companies, with expectations for significant revenue growth and multiple drug approvals in the coming years [5][6] Group 3 - The domestic pharmaceutical industry is witnessing rapid technological advancements and an acceleration in globalization, with significant transactions exceeding 10 billion USD occurring [6][7] - The industry is entering a critical period of validation for innovative drug performance, with many companies expected to launch global registration studies and new product applications [6][7] - A domestic innovative drug company projected a revenue increase of 15.84% for 2025, with a substantial net profit growth of 102.65% [7]

Market Overview - The market has entered a phase of narrow fluctuations after a series of gains, with the Shanghai Composite Index experiencing mild adjustments since January 13. The overall trend remains stable, with orderly rotation among leading sectors [1] - On Thursday, sectors such as commercial aerospace and mining led the gains, while the semiconductor sector showed signs of slowing down. Over 3,500 stocks rose, indicating improved profitability, although trading volume decreased to 2.7 trillion [1] - The current market adjustment is seen as a healthy consolidation for the spring rally, with the focus on maintaining trading volume and the rotation of hot sectors as key factors for sustaining the market momentum [1] Future Outlook - The market is expected to shift from theme-driven to fundamentals-driven momentum, although technology growth will remain the main focus. The leading sectors since the spring rally have been driven by event-based themes like commercial aerospace and brain-computer interfaces, which, despite their long-term potential, lack short-term performance support [1] - As the market enters a consolidation phase, trading volume may decline, prompting a renewed focus on sectors driven by performance and fundamentals. The primary driver for the spring rally remains the increase in market risk appetite, with technology growth sectors expected to lead the way [1] Sector Highlights - In January, technology and raw materials sectors showed strong performance, with high-dividend stocks also being a focus for potential gains in the upcoming quarterly report season [2] - Key areas of interest include AI hardware, which is expected to see significant growth leading up to 2026, and the ongoing trend of robot commercialization, which will expand into various types of robots and related components [2] - The semiconductor industry is on a path toward domestic production, with attention on semiconductor equipment, wafer manufacturing, materials, and IC design [2] - The demand for new energy materials is rising due to rapid growth in domestic and overseas energy storage needs, with signs of supply shortages and price increases expected to continue through 2026 [2] - The innovative drug sector is anticipated to enter a recovery phase after nearly four years of adjustment, with positive net profit growth expected to continue into 2026 [2]

Core Viewpoint - Recent changes in the regulatory focus for IPO applications in the semiconductor sector indicate a shift towards evaluating core technological capabilities and operational stability, rather than just fundraising amounts and project plans [1] Group 1: IPO Applications - Two semiconductor companies have withdrawn their IPO applications from the Sci-Tech Innovation Board [2] - The regulatory review process is becoming increasingly stringent, with a focus on the details of the application process [1][2] Group 2: Market Dynamics - The true direction of the market is determined by the real attitude of capital, rather than external policies or news [1] - Quantitative data can reveal hidden behaviors of capital, allowing for a clearer understanding of market dynamics [1][5] Group 3: Institutional Participation - The "institutional inventory" metric reflects whether large institutional funds are actively participating in a stock's trading, indicating its long-term value [5][9] - Stocks with active institutional inventory tend to perform better, as they have been recognized by institutions prior to market hype [7][9] Group 4: Investment Logic - The reliance on subjective judgment and emotional responses in investment decisions can lead to poor outcomes; objective, quantifiable data should guide decisions instead [10] - A shift in understanding the importance of capital's attitude over external news can enhance investment strategies and decision-making [10]